Study S000325

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0165-1875 as Monotherapy and in Combination With Semaglutide in Subjects With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT03707990
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 88
Start: 2018-10-15
Primary completion: 2019-08-13
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity and Overweight
Interventions: DRUG:NNC0165-1875; DRUG:Placebo (NNC0165-1875); DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1212-3615

Registered primary outcomes

Number of treatment emergent adverse events (TEAEs) [Day 1-36]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.